Park Square is pleased to announce the placement of Eric Martin, Ph.D. as Chief Scientific Officer at Arpeggio Biosciences. Arpeggio is an emerging biotechnology company that has developed a novel platform to directly measure gene transcription through nascent RNA sequencing and machine learning.
Dr. Martin is an experienced leader in oncology research and translational medicine. He most recently served as Senior Vice President, Translational Medicine and Science at Kinnate Biopharma. Prior, he was Director, Translational Medicine at Plexxikon, Director, Oncology Discovery Research at Ignyta, and Principal Scientist at Pfizer. He began his career as a postdoctoral fellow at the Dana-Farber Cancer Institute and Harvard Medical School.
Dr. Martin received his Ph.D. in Molecular Genetics from Thomas Jefferson University Hospitals and his B.A. in Chemistry and Fine Arts from the College of the Holy Cross.
Park Square Executive Search serves companies and institutions that are shaping the world through discovery, innovation and growth. Our clients are leading life sciences and healthcare organizations, technology companies, major research universities, and venture capital and private equity firms, including their portfolio companies. We place board members, chief executive officers, C-suite executives, and academic leaders.
![featured image](https://images.passle.net/fit-in/860x860/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/58a5d143b00e8110e83aa6e5/2022-03-03-16-42-50-384-6220f00af636ea1b345627de.jpg)